Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 15/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | DRD1 | P21728 | 2/20 | 0.68 |
| ▸ | DRD4 | P21917 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390087 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL246986 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL29798936 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL4385888 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL4393368 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3973897 | 0.96 | ADRB2 (0.92) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3842080 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3838014 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3844725 | 0.93 | ADRB2 (0.87) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3837610 | 0.93 | ADRB2 (0.86) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | claimed |
| US-20090123391-A1 | Novel Formulations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | US | claimed |
| EP-2012797-A2 | NOVEL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | claimed |
| EP-1996158-A2 | NOVEL FORMULATIONS | 3M Innovative Properties Company (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007117911-A2 | NOVEL FORMULATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007109698-A2 | NOVEL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | claimed |
| WO-2006008173-A2 | PHARMACEUTICAL FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20040059116-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-03-25 | — | — | US | claimed |
| US-6653323-B2 | Such as n-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)--2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; pulmonary diseases | THERAVANCE, INC. | 2003-11-25 | — | — | US | claimed |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | GLOBAL CASH ACCESS, L.L.C. | 2003-08-14 | — | — | US | claimed |
| WO-2003042160-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
| US-6653323-B2 | Such as n-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)--2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; pulmonary diseases | THERAVANCE, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | GLOBAL CASH ACCESS, L.L.C. | 2003-08-14 | — | — | US | disclosed |
| WO-2003042164-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003042160-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123391-A1 | Novel Formulations | PFN1, CCL11, MFAP1 | ADRB2 61/4885ADRB1 79/4885ADRB3 25/4885 |
| US-20040059116-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 7/4885 |
| US-20030153597-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885ADRB3 421/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ADRB2 1836/4885ADRB1 1307/4885ADRB3 1299/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.